Achieve Life Sciences Inc. has released a corporate presentation detailing its progress and plans related to addressing the nicotine dependence public health crisis in the United States. The company is developing cytisinicline as a potential treatment for nicotine dependence, with the aim of providing a new solution for both smoking and vaping cessation. Achieve plans to submit a New Drug Application (NDA) for smoking cessation in June 2025, with expected approval in mid-2026 and a product launch anticipated in the latter half of 2026. This would mark the first potential new FDA-approved treatment for nicotine dependence in nearly two decades. Achieve highlights the drug's potential to be highly effective and tolerable, with multiple administration routes and expanded indications. The presentation also outlines a targeted, data-driven commercial strategy leveraging AI and omnichannel communications. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.